bonfiglio john n  the wall street transcript john n bonfiglio john n bonfiglio is chief executive officer of the immune response corporation a biopharmaceutical company cofounded by medical pioneer jonas salk and based in carlsbad california prior to joining the immune response corporation dr bonfiglio was chief operating officer and executive vice president for cypress biosciences a san diegobased biotechnology firm from june  while at cypress biosciences he oversaw the firm’s business clinical and research and development efforts for its fibromyalgia drug prior to his tenure at cypress biosciences dr bonfiglio spent four years at peregrine pharmaceuticals formerly known as techniclone corporation a tustin californiabased biotechnology firm focused on cancer treatments from  to  he served as president and chief executive officer raising capital through a series of licensing agreements and equity financing agreements and created and executed a strategic plan for refocusing the company on clinical trials and licensing dr bonfiglio was vice president technology and business development of the company from  to  and oversaw research and development clinical and regulatory affairs interactions with the us food and drug administration and all productlicensing activities he also has served as a director for baxter healthcare corporation based in irvine california as director of business development and strategic planning in the immunotherapy division and later in the cardiovascular surgical division from  to  dr bonfiglio began his biotechnology career with positions at allergan inc as a scientist in  becoming a project director in  and director of business planning in  and eventually director of strategic marketing for allergan’s worldwide ocular antiinfective franchise related interviewsjohn bonfiglio  immune response corporation imnrjuly  john bonfiglio  the immune response corporation imnrjuly   cartlatest newsjames abate of centre asset management sees consumer demand driving new stock highsmalcolm e polley of stewart capital and how to play the health care stockstimothy biltz ceo of lumos networks identifies the key component for future g networksthe wall street transcript is a completely unique resource for investors and business researchersover  ceo equity analyst and money manager interviewssubscribe nowsign up for newsletter weekly email with new indepth interviews email most popular interviewsdelivering longterm results with a riskmanaged growth fundjames a abate published july   in investing strategiescompanies covered amat jnj coh rl cog nvda adbe atvi klac amzn nflx goog fb glw mu   wfm jwn cmg gps eqt rice spls buy finding investments with favorable risk and reward opportunitieshenry beukema published july   in investing strategiescompanies covered orcl msft nsrgy amzn wfm lrlcy agn lnr buy better returns and lower risk in the midcap spacemalcolm e polley published july   in investing strategiescompanies covered praa hurn fii fl nke amzn wfm wba rad buy most popular reportswireless communications  telecom published july  buy investing strategies published july  buy investing strategies published june  buy  top company interviews register for a free account to gain greater access to the wall street transcript right now ceo interviewsinterview with the president and ceo lumos networks corp nasdaqlmosinterview with the corporate vp of business development strategy and investor relations dsp group inc nasdaqdspginterview with the ceo and director tactile systems technology inc nasdaqtcmd sector roundtablesnatural gas weighs heavy on ep nearterm prospectsroundtable forumoptimism despite uncertainty in forprofit educationroundtable foruma shift in focus to natural gas from oil money manager interviewsdelivering longterm results with a riskmanaged growth fundfinding investments with favorable risk and reward opportunitiesbetter returns and lower risk in the midcap space analyst interviewsanalyzing the secular drivers within communications infrastructure and telecomsatellite companies benefiting from growth in data trafficincreased focus on content as consumers shift to digital consumption subscribe today since   the wall street transcript  terms and conditions privacy policy   httpswwwtwstcomwpadminadminajaxphp pin it on pinterest share this twitter facebook google gmail linkedin × join now for free already a member first name last name email address  create new account or create an account with a social network join with facebook join with twitter join with google username or email address  password  loginjoin now  forgot password or login using a social network log in with facebook log in with twitter log in with google page not found  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street page not found sorry the page youre looking for is not available you might want to try our homepage our most popular stories  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers john n bonfiglio  linkedin linkedin main content starts below john n bonfigliopresident and coo at tapimmune inclocationtampast petersburg florida areaindustrybiotechnologycurrenttapimmune inc tapimmune bonfiglio consulting grouppreviousoragenics inc argos therapeutics args the immune response corporationeducationpepperdine universityrecommendations person has recommended john n connectionsview john n’s full profile its freeyour colleagues classmates and  million other professionals are on linkedinview john n’s full profileexperiencepresident and cootapimmune incjuly  – present  year  monthjacksonville florida areamember board of directorstapimmunefebruary  – present  years  monthsfund raising in public markets drug development investor relations adviser to the ceoprincipalbonfiglio consulting groupnovember  – present  years  monthspresident and ceooragenics incmay  – october   years  months strategic refocusing of the company two strategic collaborations with intrexon corporation raised m in new capital qualified company for registration on nyse mkts lowered base burn rate refocused rd on therapeutic areapresident and ceoargos therapeutics argsjanuary  – february   years  monthsraleighdurham north carolina areapresident and ceothe immune response corporationjanuary  – november   years  monthschief operating officercypress bioscience –   yearceoperegrine pharmaceuticals –   yearsvice president of business developmentperegrine pharmaceuticals –   yearsdirector business developmentbaxter immunotherapy –   yearsdirector strategic marketingallergan –   yearsdirector strategic marketingallergan –   yearsscientistoccidental chemical corp –   yearskillsbiotechnologylifesciencespharmaceutical industrymedical devicesoncologycommercializationmergerstechnology transferregulatory affairsimmunologystartupsfdalicensingclinical researchstrategic planningsee mergers  acquisitionsmedical writingrdcroglpdrug developmentregulatory submissionsbusiness developmentbiopharmaceuticalsmarketingleadershipclinical trialsstrategyinfectious diseasesdrug discoveryclinical developmentventure capitalcrossfunctional team leadershipcorporate developmentsee lesshows this translationgreat•has errorsthanks for your helpeducationpepperdine universitymba businessmba business – university of california san diegophd chemisrtyphd chemisrty – suny stony brookbachelor of science bs chemistrybachelor of science bs chemistryrecommendationsa preview of what linkedin members have to say about john njohn is a ceos ceo he bleeds strategy and can hone in with laser accuracy where a companys needs are john is a natural leader who can bolster a strong steam as well as bring together disparate parties john is also selflesshis ego does not get in the way of the mission at any time he will roll up his sleeves and get into the thick of things im lucky as a business owner myself to have found another mentor leadership is synonymous with dr john bonfigliosee moresee lesssign up to see who recommended john ngroupsresearch triangle life sciences groupview john n’s full profile tosee who you know in commonget introducedcontact john n directlyview john n’s full profileview this profile in another languageenglishgermanchinese simplifiedpeople also viewedpatrick yeramianclinical research and drug developmentkathryn simonsite head regulatory  compliance at merckperry tatexxx at xxxcynthia porter mbapresident of porter research go to market ithc research companyc angel cooperdir of business operations to chief science officer at mallinckrodt pharmaceuticalsgary g altman phdbiotech and life sciences business executiverichard skowgeneral counsel  corporate secretary robin mccallumproject director at tapimmunemichael cardoneana alemanclinical research associatepublic profile badgeinclude this linkedin profile on other websitesview profile badgessearch by nameover  million professionals are already on linkedin find who you knowfirst namelast nameexample jeff weinerlinkedin member directoryabcdefghijklmnopqrstuvwxyzmorebrowse members by country tapimmune appoints dr john n bonfiglio as president and chief operating officer – tapimmune skip to content tapimmune an immunooncology company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease aboutoverview our story corporate vision company management technologyoverview pipeline clinical preclinical patents collaborations investorsoverview investor briefcase email alerts stock info financial filings faq news  eventsoverview press releases events media coverage press kit  media contact us nsdq tpiv   download quick fact sheet menu aboutoverview our story corporate vision company management technologyoverview pipeline clinical preclinical patents collaborations investorsoverview investor briefcase email alerts stock info financial filings faq news  eventsoverview press releases events media coverage press kit  media contact us tapimmune appoints dr john n bonfiglio as president and chief operating officeryou are herehomepress releasestapimmune appoints dr john n… jacksonville florida july    tapimmune inc tpiv a clinicalstage immunooncology company specializing in the development of innovative peptide and genebased immunotherapeutics and vaccines for the treatment of cancer  metastatic disease announced today that the company has appointed dr john n bonfiglio a member of its board of directors as the company’s president and chief operating officer “since joining tapimmune in early  as a strategic advisor john has been a dynamic and thoughtprovoking colleague” said glynn wilson chief executive officer “his broad experience and expertise in biotech and immunotherapy has greatly strengthened our company” “tapimmune’s strategy has never been more compelling” said dr bonfiglio “along with a team of drug development experts i am excited to lead several phase  trials and the potential to open a new investigational drug application ind for our second tcell vaccine product targeting herneu in the next  months” about tapimmune inc tapimmune inc is an immuneoncology company specializing in the development of innovative technologies for the treatment of cancer including metastasis and infectious disease the company’s peptide or nucleic acidbased immunotherapeutics comprise one or multiple naturally processed epitopes npes designed to comprehensively stimulate a patients’ killer tcells helper tcells and to restore or further augment antigen presentation by using proprietary nucleic acidbased expression systems the company’s technologies may be used as standalone medications or in combination with current treatment modalities please visit the company’s website at wwwtapimmunecom for details forwardlooking statement disclaimer this release contains forwardlooking information within the meaning of the private securities litigation reform act of  statements in this news release concerning the company’s expectations plans business outlook or future performance and any other statements concerning assumptions made or expectations as to any future events conditions performance or other matters are “forwardlooking statements” forwardlooking statements are by their nature subject to risks uncertainties and other factors which could cause actual results to differ materially from those stored in such statements such risks uncertainties and factors include but are not limited to the results of the phase ii clinical trials the ability to obtain regulatory approval of tpiv  the company’s ability to raise future financing for continued development and the ability to successfully commercialize tpiv  as well as the risks and uncertainties set forth in the company’s most recent form k q and other sec filings which are available through edgar at wwwsecgov the company assumes no obligation to update the forwardlooking statements contacts tapimmune inc glynn wilson phd chairman  ceo  share on facebook share share on twittertweet share on google plus share share on linkedin share send email mail print print category press releasesjuly   contact informationphone    email investorrelationstapimmunecom address  n laura street suite  jacksonville fl find us onfacebooktwitter company updates in the press industry news newsletter our blog press releases science publications sign up for email alerts get our news delivered to your inbox sign up today join the tpiv vip list dont miss out get our news delivered to your inbox join the tpiv vip list press releases – tapimmune skip to content tapimmune an immunooncology company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease aboutoverview our story corporate vision company management technologyoverview pipeline clinical preclinical patents collaborations investorsoverview investor briefcase email alerts stock info financial filings faq news  eventsoverview press releases events media coverage press kit  media contact us nsdq tpiv   download quick fact sheet menu aboutoverview our story corporate vision company management technologyoverview pipeline clinical preclinical patents collaborations investorsoverview investor briefcase email alerts stock info financial filings faq news  eventsoverview press releases events media coverage press kit  media contact us category archives press releasesyou are herehomecategory press releases tapimmune ceo glynn wilson to chair panel discussion on the future of combination therapies in oncology featured newsletter press releasesby aaron santosjuly  hear from randal h henderson mdprofessordepartment of radiation oncology and associate medical director at the uf health proton therapy institute and enjoy a panel discussion led by glynn wilson phd chairman  ceo of tapimmune inc tapimmune reaches  patient enrollment benchmark in phase  study of novel tcell vaccine targeting triplenegative breast cancer featured newsletter press releasesby aaron santosjune  tapimmune has enrolled   of the patients in its randomized phase  clinical study of its novel tcell vaccine candidate tpiv  for treating triplenegative breast cancer tnbc tapimmune inc enters into definitive agreements to raise  million in a private placement from accredited investors and from the exercise of warrants by existing institutional investors featured newsletter press releasesby aaron santosjune  tapimmune has entered into definitive subscription agreements to raise aggregate gross proceeds of approximately  million in a private placement transaction with accredited investors and from the exercise of certain outstanding series e warrants by certain existing institutional investors tapimmune to present at  biotechnology innovation organization international convention featured press releasesby aaron santosjune  dr glynn wilson chairman and ceo of tapimmune will present at the  biotechnology innovation organization international convention held on june  in san diego tapimmune provides first quarter  corporate and clinical update today featured press releasesby aaron santosmay  tapimmune is hosting a conference call and live audio webcast today may   at  pm et to provide a corporate and clinical update for the first quarter  tapimmune to provide first quarter  business update conference call and webcast featured newsletter press releasesby webmastermay  tapimmune inc today announced that the company will host a conference call and live audio webcast on wednesday may   at  pm et to provide a corporate and clinical update for the first quarter  richard kenney md facp joins tapimmune to lead the clinical development program featured newsletter press releasesby aaron santosmay  tapimmune announced that on may   dr richard kenney will manage tapimmune’s ongoing and planned clinical programs for its nextgeneration tcell vaccine candidates which currently include multiple phase  trials in advanced breast and ovarian cancer tapimmune announces change in management and board of directors featured press releasesby aaron santosapril  tapimmune inc announced that on april  dr john bonfiglio resigned as chief operating officer president and director of tapimmune inc to pursue other opportunities tapimmune to participate in two upcoming investor and industry conferences featured press releasesby aaron santosmarch  dr glynn wilson chairman and ceo of tapimmune will provide an overview of the company’s business clinical pipeline and partnering opportunities for its proprietary polystart technology platform during his presentation at the th annual cancer biopartnering  investment forum tapimmune provides year end  corporate and clinical update featured press releasesby webmastermarch  tapimmune today provided its first quarterly business update following the company’s uplisting to the nasdaq capital market in the fourth quarter  a public conference call and live audio webcast is scheduled for today at  pm et … sign up for email alerts get our news delivered to your inbox sign up today join the tpiv vip list dont miss out get our news delivered to your inbox join the tpiv vip list tpiv john n bonfiglio insider trades for tapimmune inc bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close tapimmune inc nasdaq tpiv go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus tapimmune inc market closed  quotes are delayed by  min jul    pm tpiv quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual john n bonfiglio dr john n bonfiglio is on the board of directors at tapimmune inc and microlin bio inc dr bonfiglio was previously employed as president chief executive officer  director by oragenics inc president  chief executive officer by intrexon corp president chief executive officer  director by transdel pharmaceuticals inc president  chief executive officer by argos therapeutics inc president  chief executive officer by immune response corp chief operating officer  executive vice president by cypress bioscience inc president  chief executive officer by peregrine pharmaceuticals inc directorbusiness planning by allergan inc directorstrategic business unit by baxter healthcare corp and president  chief executive officer by immune response corp he also served on the board at microlin bio inc old he received his undergraduate degree from stony brook university a graduate degree from the university of california san diego an mba from pepperdine university and a doctorate degree from the university of california san diego transactions date shares transaction value     award at  per share      gift at  per share      gift at  per share      derivativenonderivative trans at  per share      award at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr glynn wilson chairman president  chief executive officer mr michael j loiacono chief financial officer secretary  treasurer ms elizabeth donnelly directoradministration mr frederick gerald wasserman independent director mr mark reddish independent director mr joshua n silverman independent director ms sherry grisewood independent director dr david laskowpooley independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest awhy one analyst calls this the ‘chart of the week month and potentially year’ athe cracked benchmark why some investors want a new standard for bonds a moneymaking lessons from the richest man who ever lived age’s stock falls as jeff immelt’s th and last quarter is another disappointment anolan’s cinematic vision in ‘dunkirk’ is hollywood’s best defense against netflix aalphabet earnings a  billion hit for google potential youtube results for investors amicrosoft rides huge tax benefit from failing at smartphones to big earnings beat atrump says he has ‘complete power to pardon’ achipotle earnings media coverage of the latest illness scare will put earnings targets at risk aexxon earnings will stock trade higher on expected secondquarter beat apay tv expected to lose more than a million subscribers in latest quarter aqualcomm’s issues go beyond apple fight ayogaworks ipo pulled on valuation concerns not market conditions aamazon’s foray into groceries means more mergers of food companies experts say athis is what should really worry you about stocks aeuro rally has room to run if this pattern continues to hold true aweekend roundup companies that may cut dividends  faang stocks and market bubbles  enjoy london on the cheap aattention shoppers ‘amazon effect’ is creating bargain stocks awhy you might want to avoid these  dividend stocks astocks brace for volatility in earnings deluge fed meeting looms loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  transdel pharmaceuticals inc appoints john n bonfiglio ph d as chief executive officer and president employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       transdel pharmaceuticals inc tdlpob appoints john n bonfiglio phd as chief executive officer and president tweet   am la jolla calif oct  prnewswirefirstcall  transdel pharmaceuticals inc otc bulletin board tdlp a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform today announced the appointment of john n bonfiglio phd as chief executive officer and president dr bonfiglio will also serve as a director on transdels board of directorswith over  years of pharmaceutical industry experience dr bonfiglio brings to transdel his background in working with pharmaceutical companies during the development stage as well as those with commercialized products given his experience the board of directors is extremely pleased to have dr bonfiglio join transdel to continue to drive the vision of the company i believe that transdel has the opportunity to become a successful pharmaceutical company stated dr bonfiglio our lead product ketotransdel® has an opportunity to be the first topical ketoprofen product approved in the us and also to become a best in class product in the growing topical nsaid market i am looking forward to leading this talented team in growing the companys pharmaceutical and cosmeceutical businesses increasing shareholder value is number one on my agenda most recently dr bonfiglio worked as the president and chief executive officer of argos therapeutics in durham nc and prior to that he was the chief executive officer of the immune response corporation in carlsbad ca he was also the chief executive officer of peregrine pharmaceuticals and held senior management positions with cypress biosciences baxter healthcare and allergan inc about transdel pharmaceuticals inctransdel pharmaceuticals inc otcbb tdlp is a specialty pharmaceutical company developing noninvasive topically delivered products the companys innovativepatented transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier ketotransdel® the companys lead pain product candidate has completed a phase  clinical trial and utilizes the transdel technology to deliver the active drug ketoprofen a nonsteroidal antiinflammatory drug through the skin directly into the underlying tissues where the drug exerts its wellknown antiinflammatory and analgesic effects the company intends to leverage its transdel platform technology to expand and create a portfolio of topical products for a variety of indications the company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmeticcosmeceutical products for more information please visit httpwwwtransdelpharmacomsafe harbor statementthe company cautions you that the statements included in this press release that are not a description of historical facts are forwardlooking statements these include statements regarding the companys interpretation of the results of its phase  clinical trial for ketotransdel® the companys ability to obtain regulatory approval to market ketotransdel and the companys ability to complete additional development activities for products utilizing its proprietary transdermal delivery platform actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the companys business including without limitation the fda may not agree with the companys interpretation of the results of the phase  clinical trial for ketotransdel or may challenge the adequacy of the companys clinical trial design or the execution of the clinical trial the fda may require the company to complete additional clinical trials for ketotransdel® before the company can submit a b nda application the results of any future clinical trials may not be favorable and the company may never receive regulatory approval for ketotransdel® and the companys current need to raise additional funding to complete its product development and clinical trial plans more detailed information about the company and the risk factors that may affect the realization of forwardlooking statements is set forth in the companys filings with the securities and exchange commission including its annual report on form k and its quarterly reports on form q filed with the sec such documents may be read free of charge on the secs web site at wwwsecgov you are cautioned not to place undue reliance on these forwardlooking statements which speak only as of the date hereof all forwardlooking statements are qualified in their entirety by this cautionary statement and the company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof this caution is made under the safe harbor provisions of section e of the private securities litigation reform act of  source transdel pharmaceuticals inc read at biospacecom related news transdel pharmaceuticals inc tdlpob reports second quarter and yeartodate  results biomolecular therapeutics a new global player in rnai therapeutics launches company and adds key advisors data from transdel pharmaceuticals inc tdlpobs phase  study to be presented at th world congress on pain pharmathene inc appoints eric i richman president and chief executive officer transdel pharmaceuticals inc tdlpob to present at rodman  renshaw th annual healthcare conference ppd inc ppdi appoints former roche rhhby exec andreas tschirky as leader of bioduro llc transdel pharmaceuticals inc tdlpob presents phase  study data on ketotransdelr at world pain congress in montreal canada stem cell assurance announces appointment of mark weinreb ms as chief executive officer and board member transdel pharmaceuticals inc tdlpob to present at  southern california investor conference agile therapeutics inc appoints new president and ceo al altomari as company prepares for commercialization phase please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • transdel pharmaceuticals inc   • biotechpharma  personnel                 tapimmune appoints dr john n bonfiglio as president and chief operating officer tapimmune appoints dr john n bonfiglio as president and chief operating officer jul    et from tapimmune inc jacksonville florida july   prnewswire  tapimmune inc tpiv a clinicalstage immunooncology company specializing in the development of innovative peptide and genebased immunotherapeutics and vaccines for the treatment of cancer  metastatic disease announced today that the company has appointed dr john n bonfiglio a member of its board of directors as the companys president and chief operating officer since joining tapimmune in early  as a strategic advisor john has been a dynamic and thoughtprovoking colleague said glynn wilson chief executive officer his broad experience and expertise in biotech and immunotherapy has greatly strengthened our company tapimmunes strategy has never been more compelling said dr bonfiglio along with a team of drug development experts i am excited to lead several phase  trials and the potential to open a new investigational drug application ind for our second tcell vaccine product targeting herneu in the next  months about tapimmune inc tapimmune inc is an immuneoncology company specializing in the development of innovative technologies for the treatment of cancer including metastasis and infectious disease the companys peptide or nucleic acidbased immunotherapeutics comprise one or multiple naturally processed epitopes npes designed to comprehensively stimulate a patients killer tcells helper tcells and to restore or further augment antigen presentation by using proprietary nucleic acidbased expression systems the companys technologies may be used as standalone medications or in combination with current treatment modalities please visit the companys website at httpwwwtapimmunecom for details forwardlooking statement disclaimer this release contains forwardlooking information within the meaning of the private securities litigation reform act of  statements in this news release concerning the companys expectations plans business outlook or future performance and any other statements concerning assumptions made or expectations as to any future events conditions performance or other matters are forwardlooking statements forwardlooking statements are by their nature subject to risks uncertainties and other factors which could cause actual results to differ materially from those stored in such statements such risks uncertainties and factors include but are not limited to the results of the phase ii clinical trials the ability to obtain regulatory approval of tpiv  the companys ability to raise future financing for continued development and the ability to successfully commercialize tpiv  as well as the risks and uncertainties set forth in the companys most recent form k q and other sec filings which are available through edgar at httpwwwsecgov the company assumes no obligation to update the forwardlooking statements contacts tapimmune inc glynn wilson phd chairman  ceo  source tapimmune inc view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more aug    et preview tapimmune enters into definitive agreements to raise  million from the exercise of outstanding warrants and in a private placement from new investors jun    et preview tapimmune doses first patient in its phase  triple negative breast cancer trial for cancer vaccine tpiv  my news release contains wide tables view fullscreen read more jun    et tapimmune ceo glynn wilson to chair panel discussion on the jun    et tapimmune reaches  patient enrollment benchmark in phase  jun    et tapimmune inc enters into definitive agreements to raise  looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search transdel pharmaceuticals appoints john n bonfiglio phd as chief executive officer and  la jolla calif oct   transdel phomebiologymedicinetechnologyproductsnewsdefinitiondictionarymovieslinkssearchrssnavigation linksbiology newsmedicine newsbiology productsmedicine productsbiology definitionmedicine definitionbiology technologymedicine technologybiology dictionarymedicine dictionaryhome  medicine  technologytransdel pharmaceuticals appoints john n bonfiglio phd as chief executive officer and presidentla jolla calif oct   transdel pharmaceuwith over  years of pharmaceutical industry experience dr bonfigli i believe that transdel has the opportunity to become a successful phmost recently dr bonfiglio worked as the president and chief executi httpwwwbiomedicineorgincbiomedmedicinetechnologyasp httpfeedsbiomedicineorglatestmedicaltechnologydate la jolla calif oct  prnewswirefirstcall  transdel pharmaceuticals inc otc bulletin board tdlp a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform today announced the appointment of john n bonfiglio phd as chief executive officer and president  dr bonfiglio will also serve as a director on transdels board of directors with over  years of pharmaceutical industry experience dr bonfiglio brings to transdel his background in working with pharmaceutical companies during the development stage as well as those with commercialized products  given his experience the board of directors is extremely pleased to have dr bonfiglio join transdel to continue to drive the vision of the company   i believe that transdel has the opportunity to become a successful pharmaceutical company stated dr bonfiglio  our lead product ketotransdel® has an opportunity to be the first topical ketoprofen product approved in the us and also to become a best in class product in the growing topical nsaid market i am looking forward to leading this talented team in growing the companys pharmaceutical and cosmeceutical businesses  increasing shareholder value is number one on my agenda   most recently dr bonfiglio worked as the president and chief executive officer of argos therapeutics in durham nc and prior to that he was the chief executive officer of the immune response corporation in carlsbad ca  he was also the chief executive officer of peregrine pharmaceuticals and held senior management positions with cypress biosciences baxter healthcare and allergan inc   about transdel pharmaceuticals inc transdel pharmaceuticals inc otcbb tdlp is a specialty pharmaceutical company developing noninvasive topically delivered products the companys innovativepatented transdel™ cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier  ketotransdel® the companys lead pain product candidate has completed a phase  clinical trial and utilizes the transdel™ technology to deliver the active drug ketoprofen a nonsteroidal antiinflammatory drug through the skin directly into the underlying tissues where the drug exerts its wellknown antiinflammatory and analgesic effects the company intends to leverage its transdel™ platform technology to expand and create a portfolio of topical products for a variety of indications  the company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmeticcosmeceutical products  for more information please visit httpwwwtransdelpharmacom safe harbor statement the company cautions you that the statements included in this press release that are not a description of historical facts are forwardlooking statements these include statements regarding the companys interpretation of the results of its phase  clinical trial for ketotransdel® the companys ability to obtain regulatory approval to market ketotransdel and the companys ability to complete additional development activities for products utilizing its proprietary transdermal delivery platform actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the companys business including without limitation the fda may not agree with the companys interpretation of the results of the phase  clinical trial for ketotransdel or may challenge the adequacy of the companys clinical trial design or the execution of the clinical trial the fda may require the company to complete additional clinical trials for ketotransdel® before the company can submit a b nda application the results of any future clinical trials may not be favorable and the company may never receive regulatory approval for ketotransdel® and the companys current need to raise additional funding to complete its product development and clinical trial plans more detailed information about the company and the risk factors that may affect the realization of forwardlooking statements is set forth in the companys filings with the securities and exchange commission including its annual report on form k and its quarterly reports on form q filed with the sec such documents may be read free of charge on the secs web site at wwwsecgov you are cautioned not to place undue reliance on these forwardlooking statements which speak only as of the date hereof all forwardlooking statements are qualified in their entirety by this cautionary statement and the company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof this caution is made under the safe harbor provisions of section e of the private securities litigation reform act of  source transdel pharmaceuticals inccopyright pr newswireall rights reservedgoodrelated medicine technology  transdel pharmaceuticals advances lead topical pain drug into phase  program transdel initiates ketotransdeltm phase  clinical program for pain transdel enrolls first patient for ketotransdeltm phase  clinical trial transdel pharmaceuticals to webcast presentation at th annual biocom investor conference transdel pharmaceuticals announces management reorganization transdel pharmaceuticals presents phase  study data on ketotransdel® at world pain congress in montreal canada auxilium pharmaceuticals inc receives clearance to resume clinical trials for xiaflextm vion pharmaceuticals completes accrual of  patients to its pivotal phase ii trial of cloretaziner vnpm in elderly aml solvay pharmaceuticals inc and wyeth pharmaceuticals announce receipt of an fda action letter for bifeprunox an investigational treatment for schizophrenia callisto pharmaceuticals opens additional sites for phase ii clinical trial of atiprimod in advanced carcinoid cancer patients wallstnet wwwwallstnet updates the investment community through an allnew interview with regenerx biopharmaceuticals ceo post your comments namecomment email date july    medx holdings inc the manufacturer  strengthening and rehabilitation equipment today announced the national roll  is considered the gold standard for the treatment of  medical strengthening equipment  the physician or practice who prescribe the medx home  date   centurion medical products a leader in medical product innovation  impaction removal device for hospice patient care  centurion medical products  patient pain management and emotional comfort are part of  patient pain while preventing unneeded emergency department admission due to severe  date  eli lilly and company nyse lly  has  pending patent litigation in the us district court for the  cialis ® tadalafil unit dose patent this patent was  of the agreement cialis exclusivity is now expected to end  unit dose patent for cialis is valid and infringed by  breaking medicine technology medx announces national roll out of home back machine program centurions disimpactor for hospice fecal impaction solution reduces pain and possible admission to emergency department lilly reaches settlement agreement in us cialis patent litigationdate  july     west dermatology is pleased to  pac beginning july   ms vu will join west dermatology’s large network of  in dermatology skin cancer  and more she graduated from the university of  date  july     how  are on the rise say researchers presenting their work at the american   “the combination of evaluating the patterns of change in concussion symptom presentation  date  july     acute myeloid leukemia  that progresses rapidly without treatment newly diagnosed patients face intense chemotherapy regimens and  and relapse with such a challenging diagnosis that requires immediate action patients  date  july     for individuals with extended hospital  adjustable beds used in such facilities are specially designed to accommodate patients with a   an inventor from rochester ind has invented the patentpending portable arm rest  date      doctors on liens the leading network of medical providers  directed by dr russell horine dc to their exclusive list of medical professionals horine  horine serving as the clinic director and his son dr lee horine and daughterinlaw  breaking medicine news mins west dermatology fresno happy to announce july arrival of “tu” tuantu doan vu pac assessing concussion symptom presentation may provide insight into rise in rates the leukemia  lymphoma society and platformq health present virtual education event for cancer patients with acute myeloid leukemia aml adjustable and portable arm support device invented by inventhelp client ipl doctors on liens announces partnership with distinguished chiropractors in the central valleybiology navigationaidshivbioinformaticsbiotechnologybiochemistrycancercell biologydevelopmental biologyecologyenvironmentevolutionfood technologygenegeneticsgenomicshealthmedicineimmunologymicroarraymicrobiologymolecularmarine biologynanobiotechnologyneurobiologyplant sciencesstem cellsystems biologyviruswomen healthmedical navigationabortionachesadhdaddictionalcoholallergyalternative medicinealzheimers dementiaanxietystressarthritisautismbacteriabloodbird fluavian flubonesbreast cancercancercardiovascularcervical cancerchikungunyacholesterolclinical trialscolorectal cancerconferencescrohnscystic fibrosisdenguedentistrydepressiondiabetesdrugeating disorderseducationepilepsyerectile dysfunctioneye healthblindnessfertilityflucoldgastrointestinalgeneticsgoutheadachemigrainehearingdeafnesshivaidshuntingtons diseasehypertensionimmune systemvaccinesinsuranceinfectious diseasesirritablebowel syndromeinternetleukemialifestyleliver diseasehepatitislung cancerlupusmad cow diseasemedical devicesmedical studentstrainingmedicaremedicaidmedicomens healthmental healthmriultrasoundmrsadrug resistancemultiple sclerosismuscular dystrophyneurologynursingnutritiondietobesityweight losspainanestheticsparkinsons diseasepediatricschildrens healthpharmabiotech industrypharmacypharmacistspregnancyprematureprostatepsychologypsychiatryrehabilitationrespiratoryasthmasarsschizophreniaseniorsagingsexual healthsleepsleep disorderssmokingstatinsstem cell researchstrokesurgerytransplantsorgan donationsviruseswater  air qualitywomens healthcopyright   biomedicine all rights reservedabout  contact us  disclaimer  privacy policy  terms and conditions tapimmune appoints john n bonfiglio phd to its board of directors tapimmune appoints john n bonfiglio phd to its board of directors accomplished biotech ceo is currently a strategic advisor to tapimmune jul    et from tapimmune inc seattle july   prnewswire  tapimmune inc otcmkts tpiv is pleased to announce the appointment of john n bonfiglio phd mba to its board of directors  since february  dr bonfiglio has been a strategic advisor to the management team assisting with financing development and implementation of an improved capital markets and shareholder irpr program dr bonfiglio is a highly successful biotech ceo with broad experience in corporate strategy financing market interactions and business development  most recently dr bonfiglio served as president and ceo of oragenics where he refocused the company and raised over  million dollars in the public markets while positioning the company for a successful relisting on the new york stock exchange nyse prior to joining oragenics he served as president and ceo of argos therapeutics where he raised over  million dollars for the company and led the company in a successful phase  study in renal cell carcinoma  as president and ceo of the immune response corporation he was responsible for turning the company around through improved therapeutic focus capital raising over  million and improved investor relations resulting in a significant appreciation in stock price and shareholder value   dr bonfiglio also served as president and ceo of peregrine pharmaceuticals and director of business development at baxter healthcare corporations immunotherapy division john received his phd from the university of california san diego and an mba from pepperdine university dr glynn wilson chairman  ceo of tapimmune stated we welcome john to the tapimmune board of directors  for the past six months john has been working as a strategic advisor to the management team his input has had a measureable impact on the advances we have made in the areas of investor and shareholder communications as well as technical and clinical development as our newest board member we look forward to drawing more deeply on his broad experience and success as a biotech executive  his deep industry background will to enhance the overall capabilities of the board as we enter phase ii clinical trials and the next phase of our growth about tapimmune inc tapimmune inc is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious disease the companys peptide or nucleic acidbased immunotherapeutics comprise one or multiple naturally processed epitopes npes designed to comprehensively stimulate a patients killer tcells helper tcells and to restore or further augment antigen presentation by using proprietary nucleic acidbased expression systems the companys technologies may be used as standalone medications or in combination with current treatment modalities please visit the companys website at wwwtapimmunecom for details  forwardlooking statement disclaimer  this release contains forwardlooking information within the meaning of the private securities litigation reform act of  statements in this news release concerning the companys expectations plans business outlook or future performance and any other statements concerning assumptions made or expectations as to any future events conditions performance or other matters are forwardlooking statements forwardlooking statements are by their nature subject to risks uncertainties and other factors which could cause actual results to differ materially from those stored in such statements such risks uncertainties and factors include but are not limited to the risks set forth in the companys most recent form k and other sec filings which are available through edgar at wwwsecgov the company assumes no obligation to update the forwardlooking statements contacts tapimmune inc glynn wilson phdchairman  ceo pcg advisorykirin m smithchief operations officer sean leouschief communications officer wwwpcgadvisorycom source tapimmune inc related links httpwwwtapimmunecom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more sep    et preview tapimmune inc to present at th annual rodman  renshaw healthcare conference jun    et preview tapimmune reports robust immune responses generated in  of  evaluable herneu breast cancer patients my news release contains wide tables view fullscreen read more jun    et tapimmune ceo glynn wilson to chair panel discussion on the jun    et tapimmune reaches  patient enrollment benchmark in phase  jun    et tapimmune inc enters into definitive agreements to raise  looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip whats your age submit i dont know skip background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming check for social media accounts this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip